Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Recommendation of “Hold” from Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNC) has been assigned a consensus rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.39.

Several research analysts have issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Mizuho decreased their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. StockNews.com initiated coverage on Revance Therapeutics in a research note on Tuesday. They issued a “hold” rating on the stock. Finally, Barclays decreased their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd.

Institutional Trading of Revance Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Natixis bought a new stake in Revance Therapeutics during the 4th quarter valued at approximately $31,000. FORA Capital LLC bought a new stake in Revance Therapeutics during the 3rd quarter valued at approximately $54,000. Two Sigma Securities LLC bought a new stake in Revance Therapeutics during the 4th quarter valued at approximately $35,000. Alpine Global Management LLC bought a new stake in Revance Therapeutics during the 4th quarter valued at approximately $37,000. Finally, Accredited Investors Inc. bought a new stake in Revance Therapeutics during the 3rd quarter valued at approximately $67,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Monday. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The stock’s 50-day simple moving average is $3.62 and its two-hundred day simple moving average is $4.26. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $6.65.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.